These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19263796)

  • 1. [Erythropoietin: a new perspective in cardiovascular therapy].
    Raddino R; Robba D; Caretta G; Bonadei I; Teli M; Zanini G; Madureri A; Vizzardi E; Dei Cas L
    Monaldi Arch Chest Dis; 2008 Dec; 70(4):206-13. PubMed ID: 19263796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin: new horizon in cardiovascular medicine.
    Koul D; Dhar S; Chen-Scarabelli C; Guglin M; Scarabelli TM
    Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):5-12. PubMed ID: 18221097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular effects of erythropoietin: anemia and beyond.
    Guglin ME; Koul D
    Cardiol Rev; 2006; 14(4):200-4. PubMed ID: 16788333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin in cardiovascular diseases.
    van der Meer P; Voors AA; Lipsic E; van Gilst WH; van Veldhuisen DJ
    Eur Heart J; 2004 Feb; 25(4):285-91. PubMed ID: 14984916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current perspectives on protective roles of erythropoietin in cardiovascular system: erythropoietin receptor as a novel therapeutic target.
    Kagaya Y; Asaumi Y; Wang W; Takeda M; Nakano M; Satoh K; Fukumoto Y; Shimokawa H
    Tohoku J Exp Med; 2012 Jun; 227(2):83-91. PubMed ID: 22688525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside.
    Lipsic E; Schoemaker RG; van der Meer P; Voors AA; van Veldhuisen DJ; van Gilst WH
    J Am Coll Cardiol; 2006 Dec; 48(11):2161-7. PubMed ID: 17161240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis?
    Timmer SA; De Boer K; Knaapen P; Götte MJ; Van Rossum AC
    J Card Fail; 2009 May; 15(4):353-61. PubMed ID: 19398085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects.
    Manolis AS; Tzeis S; Triantafyllou K; Michaelidis J; Pyrros I; Sakellaris N; Kranidis A; Melita H
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Oct; 5(5):355-75. PubMed ID: 16248829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cardiovascular effects of erythropoietin.
    Smith KJ; Bleyer AJ; Little WC; Sane DC
    Cardiovasc Res; 2003 Sep; 59(3):538-48. PubMed ID: 14499855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of the erythropoietin/erythropoietin receptor system as a novel cardiovascular therapeutic target.
    Satoh K; Fukumoto Y; Nakano M; Kagaya Y; Shimokawa H
    J Cardiovasc Pharmacol; 2011 Dec; 58(6):570-4. PubMed ID: 21934628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New applications of erythropoietin in cardiovascular disease: from haematopoiesis to cardiac protection].
    van der Meer P; van Veldhuisen DJ
    Ned Tijdschr Geneeskd; 2008 Apr; 152(16):923-7. PubMed ID: 18561787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin and the heart: facts and perspectives.
    Mastromarino V; Volpe M; Musumeci MB; Autore C; Conti E
    Clin Sci (Lond); 2011 Jan; 120(2):51-63. PubMed ID: 20929439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure, production and function of erythropoietin: implications for therapeutical use in cardiovascular disease.
    Mocini D; Leone T; Tubaro M; Santini M; Penco M
    Curr Med Chem; 2007; 14(21):2278-87. PubMed ID: 17896976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of erythropoietin in myocardial protection: potential mechanisms and applications.
    Schwartzenberg S; Ben-Shoshan J; Keren G; George J
    Expert Rev Cardiovasc Ther; 2006 Jan; 4(1):41-50. PubMed ID: 16375627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin and the vascular wall: the controversy continues.
    Jelkmann W; Elliott S
    Nutr Metab Cardiovasc Dis; 2013 Dec; 23 Suppl 1():S37-43. PubMed ID: 22682530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pleiotropic effects of erythropoietin].
    Kes P; Basić-Jukić N; Furić-Cunko V
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():46-53. PubMed ID: 20232551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Erythropoietin: pleiotropic actions].
    Buemi M; Donato V; Bolignano D
    Recenti Prog Med; 2010 Jun; 101(6):253-67. PubMed ID: 20672574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The non-haematopoietic biological effects of erythropoietin.
    Arcasoy MO
    Br J Haematol; 2008 Apr; 141(1):14-31. PubMed ID: 18324962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin and renoprotection.
    Bahlmann FH; Fliser D
    Curr Opin Nephrol Hypertens; 2009 Jan; 18(1):15-20. PubMed ID: 19077684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of erythropoietin in cardiovascular disease: erythropoiesis and beyond.
    Westenbrink BD; Voors AA; Ruifrok WP; van Gilst WH; van Veldhuisen DJ
    Curr Heart Fail Rep; 2007 Sep; 4(3):127-33. PubMed ID: 17883987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.